The inspection covered product development services, such as technology transfer, analytical method validation and stability testing, as well as contract manufacturing.
Bill Wedlake, NextPharma’s CEO, said: “This positive endorsement of our Waltrop site is another major step for NextPharma in its objective to be the leading provider of World Class, quality pharmaceutical product development and contract manufacturing services to the global pharmaceutical and biotechnology market.”